The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Abstract
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. Participants were randomly assigned to receive the combination of semaglutide 2.4 mg and cagrilintide 2.4 mg (CagriSema) or placebo. The estimated mean change in body weight from baseline to week 68 was -20.4% with CagriSema compared to -3.0% with placebo. Gastrointestinal adverse events occurred in 79.6% in the CagriSema group vs 39.9% in the placebo group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cagrilintide 2•4 mg/week; semaglutide 2•4 mg/week for 68 weeks 17•3% (16•6-18•1) vs placebo; 5•5% (4•3-6•7) vs semaglutide alone 0•4% (not more than the effect of semaglutide alone) Improved physical function (based on IWQOL-Lite-CT and SF-36v2 scores); drug discontinuation due to adverse events 5•9%; weight plateau not reached Garvey et al (2025) 135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“In adults with overweight or obesity, cagrilintide-semaglutide reduced bodyweight by 17•3% (16•6-18•1; placebo-subtracted), 135 along with reductions in waist circumference, blood pressure, and improved physical functioning scores.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“Gastrointestinal adverse events were slightly more frequent with CagriSema than with semaglutide alone.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“The effects of the drug combination were greater than the effects of either medication alone, but less than the sum of effects for both medications.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“In the REDEFINE 1 trial, coadministration of cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (CagriSema) resulted in a 20.4% mean Weight loss at 68 weeks in adults with overweight or obesity.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [78]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citation2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Self-citationWeight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Cited by
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Self-citationNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationBrain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 80
“…(an oral small-molecule GLP-1RA), survodutide (a GCGR–GLP-1R co-agonist), retatrutide (a GIPR–GCGR– GLP-1R triple agonist), maridebart cafraglutide (Maritide; a GIPR antagonist–GLP-1R agonist) and cagrilintide–semaglutide (Cagri-Sema; a co-formulated amylin and GLP-1R agonist) 4,90–98 (Table 2).”
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 49
Metadata
- Authors
- Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. H.
- Affiliations
- University of Alabama at Birmingham (US)
- Helmholtz Munich (DE)
- Novo Nordisk, Søborg, Denmark
- University of Leicester (GB)
- University of Helsinki (FI)
- Washington Center for Weight Management and Research (US)
- University of Rome Tor Vergata (IT)
- University of Pennsylvania (US)
- Novo Nordisk (Denmark) (DK)
- University of Liverpool (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-08-14
- Volume
- 393
- Issue
- 7
- Pages
- 635-647
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4411522078
- Semantic Scholar
- 88a7f366045169f809d813a8da85f107c6d472ed
- Cited by
- 238
- References
- 32
- Citations by year
- 2026: 181 · 2025: 57
- FWCI
- 133.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- cagrilintide, semaglutide, combination therapy, obesity, overweight, weight loss, GLP-1 receptor agonists, GIP receptor agonist, obesity-related comorbidities, lifestyle intervention, treatment policy estimand, cardiovascular outcomes, GIP/GLP-1 receptor agonist
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Hypertension, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Dyslipidemias, Overweight, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. https://app.cochat.ai/papers/10.1056/nejmoa2502081
- The paper
- Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. H. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2502081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.